ArticleAdvances in virology2012
Molecular Understanding of HIV-1 Latency.
Article in Advances in virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.Signal transduction and targeted therapy · 2024Trial
- Polyphenol Extracts from Grape Seeds and Apple Can Reactivate Latent HIV-1 Transcription through Promoting P-TEFb Release from 7SK snRNP.Disease markers · 2022Article
- An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review.Pharmacological reports : PR · 2021Review
- Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.Cell host & microbe · 2018Review
- The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells.Oncotarget · 2017Article
- Periodontal and other oral manifestations of immunodeficiency diseases.Oral diseases · 2017Review
- Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs.Viruses · 2017Review
- HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.Journal of virology · 2016Article
- Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.Veterinary sciences · 2015Review
- Review
- Article
- Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency.PloS one · 2015Article
- Dilazep synergistically reactivates latent HIV-1 in latently infected cells.Molecular biology reports · 2014Article
- HIV-1 latency in monocytes/macrophages.Viruses · 2014Review
- Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.Antiviral chemistry & chemotherapy · 2014Review
- The macrophage: a therapeutic target in HIV-1 infection.Molecular and cellular therapies · 2014Review
- HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.Retrovirology · 2013Article
- Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.Journal of virology · 2013Article
- Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Expert opinion on biological therapy · 2013Review
- TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?Mediators of inflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of highly active antiretroviral therapy (HAART) has been an important breakthrough in the treatment of HIV-1 infection and has also a powerful tool to upset the equilibrium of viral production and HIV-1 pathogenesis. Despite the advent of potent combinations of this therapy, the long-lived HIV-1 reservoirs like cells from monocyte-macrophage lineage and resting memory CD4+ T cells which are established early during primary infection constitute a major obstacle to virus eradication. Further HAART interruption leads to immediate rebound viremia from latent reservoirs. This paper focuses on the essentials of the molecular mechanisms for the establishment of HIV-1 latency with special concern to present and future possible treatment strategies to completely purge and target viral persistence in the reservoirs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.